Event Details
September 01, 2015
Description
Expected final decision by European Commission on Marketing Authorization Application
Participants (3)
| Name | Type | Mentions | |
|---|---|---|---|
| European Commission | person | 2 | View Entity |
| Regeneron | organization | 22 | View Entity |
| Sanofi | organization | 26 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_025891.jpg
This document is a press release or investor relations update from Sanofi and Regeneron dated around July 2015, detailing clinical trial results, pricing, and regulatory milestones for the cholesterol drug Praluent. It announces a positive opinion from the European Medicine Agency and schedules an investor conference call for July 24, 2015. The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production to Congress, likely related to pharmaceutical pricing or regulatory investigations, though it contains no direct mentions of Jeffrey Epstein or his associates in this specific page.
Related Events
Events with shared participants
Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent.
2015-07-24 • Teleconference / Webcast
The European Commission is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union.
2015-09-01 • European Union
Investor Relations Conference Call on Praluent for the financial community.
2015-07-24 • Teleconference / Webcast
Trading of Regeneron shares was halted pending news.
Date unknown
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
European Commission expected to release a draft act to authorize CBD (future tense in document).
2019-10-01 • EU
ODYSSEY clinical trial program.
2025-12-01
UN-sponsored donors conference on Yemen
2017-05-01 • Geneva
Investor Relations Conference Call on Praluent hosted by Sanofi and Regeneron
2015-07-24 • Conference Call / Webcast
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event